Biotech Series B Investors & VC Firms
724 firms in this list, with a median first check of $500K. 165 of them lead rounds. Generated from verified public data and updated continuously.
Voima Ventures
HelsinkiPre-Seed–Series B$216K – $3.2M
11 people
Sampac Tech Fund
Palo AltoSeed–Late Stage
31 people
Beyond Ventures
Hong KongSeed–Series B$100K – $5M
16 people
K3 Ventures
SingaporeSeed–Growth
20 people
Panacea Venture
SingaporeSeed–Late Stage
22 people
Windham Capital Partners
New YorkSeries A–Growth$1M – $5M
17 people
Angel Bridge Co.,Ltd.
TokyoSeed–Series B$70K – $33M
9 people
Dentsu Ventures
TokyoSeed–Late Stage
12 people
UKSE
SheffieldSeries A–Late Stage
34 people
SciFi VC
San FranciscoPre-Seed–Series B$100K – $1M
7 people
Remgro / Invenfin ecosystem
StellenboschSeed–Growth
21 people
TCG Crossover
Palo AltoSeed–Late Stage
25 people
Mitsui Global Investment
Menlo ParkPre-Seed–Late Stage$500K – $10M
12 people
KOMPAS VC
HørsholmPre-Seed–Series B$1.1M – $5.4M
15 people
Lilly Asia Ventures
Hong KongPre-Seed–Series C
3 people
Magna Investment
SeoulSeed–Growth
17 people
PortfoLion Capital Partners
BudapestSeed–Growth$540K – $32.4M
31 people
Xeraya Capital
Kuala LumpurSeed–Growth
22 people
Adjuvant Capital
New YorkSeries A–Series B$10M – $25M
19 people
BeiGene
ChangpingSeries A–Series B
38 people
Solas BioVentures
ChattanoogaPre-Seed–Series B
17 people
LAV
Hong KongSeed–Series C$5M – $15M
3 people
Brightlands Venture Partners
GeleenSeed–Series B$540K – $2.2M
14 people
i-nest capital
TokyoSeed–Growth
7 people
Related lists
Series B Investors & VC Firms (2951)Biotech Investors & VC Firms (2483)Biotech Seed Investors & VC Firms (2027)Series B Investors & VC Firms in North America (1738)Biotech Series A Investors & VC Firms (1627)Biotech Investors & VC Firms in North America (1601)Series B Investors & VC Firms in United States (1573)Biotech Investors & VC Firms in United States (1450)SaaS Series B Investors & VC Firms (1075)Series B Investors & VC Firms in Europe (1073)
Data sourced from public filings and firms' own websites — see our methodology.





























































































